… limited by the need to derive antigen-presenting cells (APC) from patients or … CD4 + T
cell–targeted synthetic microbead-based artificial APC (aAPC) and used them to activate CD4 + T …

… Combined, these cellular attributes characterize T cells with antitumor properties that may
… IL4, IL5, and IL13 were detected in response to peptide-pulsed T2 cells but not to control T2 …

… CD4 + T cell-targeted … antitumor CTLs, therefore increasing the efficiency of the adoptive
immunotherapy of cancer. In this report, whether the bead-based aAPCs injection could elicit …

… to T-cells to elicit a potent anti-tumor immune response … directly to T-cells or indirectly via
antigen-presenting dendritic cells. … natural APCs, and are referred to as artificial APCs (aAPCs). …

… in vivo would elicit therapeutic antitumor CTL response. We … vivo and elicited much stronger
protective CTL response than … DCs are probably the most potent antigen presenting cells …

… II + antigen-presenting cells (APC) in contralateral LNs or when transferred to tumor-free
mice. We also report that the use of artificial … competence of CD4 + T-cell–targeted therapeutic …

… of heterogeneous professional antigen presenting cells (APCs… and artificial modification,
induction of immune response may … elicit apparent antibody responses, CD4 + and CD8 + T cell …

… strategy to enhance T cell–targeted immunotherapy. … of synthetic CDNs that activate STING
stimulates antitumor … into the induction of IFNs by antigen-presenting cells, we treated bone …

… , dendritic cell-based vaccines, artificial antigen-presenting cells, and … to elicit broad-epitope
CD8 + and CD4 + T-cell responses. In … , which primed anti-tumoral CD8 + T cell responses in …

… specific immune responses were elicited with viral vectors [49–51]. As antitumor vaccines have
… Interestingly, the protective capacity of the nontargeted vaccine was superior to that of the …